Home Alzheimer’s Disease Addition of Cediranib to Olaparib Fails to Induce Superior PFS in Platinum-Censitive...

Addition of Cediranib to Olaparib Fails to Induce Superior PFS in Platinum-Censitive Ovarian Cancer

A study designed to evaluate the addition of cediranib to olaparib (Lynparza) failed to meet its primary end point of improved progression-free survival (PFS), compared with chemotherapy, according to results presented at the 2020 ASCO Virtual Scientific Program.

However, study data suggested the combination showed comparable activity to standard of care platinum-based chemotherapy treatment for recurrent platinum-sensitive ovarian cancer. More, both olaparib alone and the cediranib/olaparib combination demonstrated substantial activity for patients with a germline BRCA (gBRCA) mutation.

“Three clinical studies have suggested the potential for synergy between anti-angiogenics and PARP inhibitors,” lead study author Joyce F. Liu, MD, MPH, of the Dana-Farber Cancer Institute, explained in the study’s presentation. “In pre-clinical studies in ovarian cancer cell lines, synergy…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments